Skip to main content


Video computer laptop call telehealth telemedicine

Telemedicine Updates

Dec 08, 2022

Several recent articles inform us of recent trends in Telemedicine.

Read Article
cancer search news magnify

Xeljanz Cancer Risks Detailed

MedPage Today
Dec 07, 2022

The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study.

Tofacitinib at either 5 or 10 mg twice daily in the so-called ORAL

Read Article

Bimekizumab Efficacy in TNF-Refractory Psoriatic Arthritis

Dec 07, 2022

Bimekizumab, a selective inhibitor of interleukin (IL)-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active psoriatic arthritis who previously failed therapy with tumour necrosis factor-α (TNFi) inhibitors.

The BE COMPLETE study was a phase

Read Article

Multi-ancestry analysis reveals novel genetic loci associated with Osteoarthritis

Dec 06, 2022

The first large multi-ancestry genetics study of osteoarthritis (OA) has found 10 novel OA-associated genetic loci, and results showed some of the OA-associated regions are robustly found in every population ancestry studied. 

Read Article

Lupus Linked With Greater Risk of Cardiovascular Complications of Childbirth

Dec 02, 2022

Pregnant women with systemic lupus erythematosus (SLE) were more prone to cardiovascular complications during delivery, and their risk seems to have increased over the past 15 years, according to national administrative data.

The cross-sectional study supports the role that the

Read Article
COVID.virus_.corona.jpg (keep)

Rheum Drugs & IDSA Guidelines to Treat COVID-19

Dec 01, 2022

The Infectious Diseases Society of America has recently updated its recommendations with regards to the treatment of severely ill, hospitalized COVID-19 infected patients and also about the appropriate use of anti-IL-6, JAKs and colchicine.

Read Article


Dec 01, 2022

A UK study suggests the equivalent outcomes when patients with interstitial lung disease (ILD) associated with connective tissue disease (CTD) are treated with either intravenous rituximab (RTX) or cyclophosphamide (CTX), but with fewer adverse events with RTX. 

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

Just Can’t Get Enough of Hydroxychloroquine

Nov 30, 2022

When it comes to hydroxychloroquine dosing, issues on efficacy, toxicity and therapeutic thresholds may affect the optimal use of this important drug.

Following are three abstracts presented during the meeting that address these topics.

Read Article

Low Dose IL-2 Therapy in Sjögren’s

Nov 29, 2022

There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that low-dose interleukin 2 (LD-IL-2) was effective effective and well tolerated in patients with primary Sjögren’s syndrome (pSS), with evidence of restored immune balance.

Read Article
lupus SLE

Tyk2 Inhibition Effective in SLE

Nov 28, 2022

Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients.

The results of this phase II trial were recently presented at ACR 2022. This  phase II multinational trial enrolled 363 adults with

Read Article

How Underweight Women Can Reduce Hip Fracture Risk

Nov 28, 2022

How women can reduce the risk of hip fracture?  

Read Article
Vegetarian diet food nutrition

Will a vegetarian diet and exercise actually help RA disease activity?

Nov 25, 2022

The exact role of diet, physical activity, and stress management in the management of RA has long been debated. While reasonable evidence has supported the importance of physical activity in patients with RA, its capacity to reduce disease activity via conventional measures such as DAS28 was

Read Article
scale decision balance question

The disconnect between objective inflammatory response and PROs in AxSpA

Nov 23, 2022

The assessment of disease activity in AxSpA involves the use of objective inflammatory response (OIR) and patient reported outcomes (PROs). In clinics, a combination of OIR and PROs are used to measure disease activity and response to treatment. OIR includes measurements such as CRP and MRI

Read Article

RA: MACE Events with Opioids vs. NSAIDs

Addressing chronic pain often leads general practitioners and specialists to prescribe opioids. However, opioids (weak and strong) have not demonstrated efficacy in long-term pain management; their chronic use could even worsen pain in users. Opioids prescription is often perceived as being

Read Article

SLE: Variability in Racial Disparities in Pregnancy Outcomes

Significant disparities exist in pregnancy outcomes in women with systemic lupus erythematosus (SLE), with previous cohorts identifying Black women as having a higher risk of maternal mortality compared to White women with SLE.

Read Article
signs treat

Why treatment of pre-RA isn't ready for prime time

The ACR Great Debate was on "To treat or not to treat in pre-RA?". What is the clinician to do?

Read Article
RheumNow Podcast square

ACR 2022 Appraisal, Praise & Critique (11.18.2022)

Nov 18, 2022

It was great to be back at an ACR annual meeting, this one in Philadelphia - Philly was great. A walking town, rich in culture, history and good places to meet and mingle. 

I loved the city, but not the convention center (not easy to navigate). 

The meeting itself was very

Read Article
Best of

ACR Best Abstracts - Day 3

Nov 14, 2022

The last day was jammed with important reports and research including the late breaking abstracts. 


Read Article
ACR Best

ACR Best Abstracts - Day 2

Nov 13, 2022

Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more.

Here are the RheumNow faculty selections for #ACRbest abstracts today:

Read Article
covid coronavirus virus

Does Evusheld shield people living with rheumatic diseases?

While COVID vaccination and subsequent booster remain the cornerstone, pre-exposure prophylaxis such as Evusheld (tixagevimab and cilgavimab) has been approved by FDA in December 2021 and EMA in March 2022 for people immunocompromised either due to a medical condition or receiving treatment with

Read Article
Performance BASDAI & ASDAS in evaluating PsA axial symptoms? 400+ pts DISCOVER 1&2 Weak correlations w/ peripheral arthritis Moderate/strong correlations w/ fatigue & pain Both perform similarly but do they perform well enough? #ACR22 @Rheumnow
Holding hands

SLE, Sex and STDs

Nov 13, 2022

Once in a while, I find an abstract at the ACR meeting that can potentially save lives and be implemented in practice now.  

In Abstract #0939, Dr. J Patricia Dhar and colleagues shared data from a pilot study examining a new method to monitor cervical health in African American Women with

Read Article
injection needle

TNFi cycling in axSpA: Results from CorEVITAS Registy study

Nov 13, 2022

Data presented at ACR22 shows that cycling through TNFi in axSpA patients with primary lack of efficacy with first line TNFi has limited additional benefit in controlling disease. 

Read Article
Puzzle pieces

Where are we with treating Pre-Rheumatoid Arthritis?

The ability to prevent RA in individuals at risk is a holy grail in rheumatology. There is a long history dating back to the PROMPT trial of methotrexate and PRAIRIE trial of rituximab. Both otrials showed an effect, but it seemed more likely to be a delaying of RA than prevention or modulation

Read Article
Checklist survey

Are MDA criteria created equal in PsA?

Nov 13, 2022

Minimal Disease Activity criteria are used to evaluate PsA disease activity and response to treatment. Given that a patient only has to meet 5 of the 7 criteria, should the individual components be weighted equally? 

Read Article